Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

266
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
266
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.3K
Clinical Trials01:16

Clinical Trials

10.0K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.0K
Controls in Experiments01:13

Controls in Experiments

14.4K
When conducting an experiment, it is crucial to have control to reduce bias and accurately measure the dependent variables. It also marks the results more reliable. Controls are elements in an experiment that have the same characteristics as the treatment groups but are not affected by the independent variable. By sorting these data into control and experimental conditions, the relationship between the dependent and independent variables can be drawn. A randomized experiment always includes a...
14.4K
Blinding01:11

Blinding

3.7K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.7K
Hazard Ratio01:12

Hazard Ratio

377
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
377

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ocular speech tracking persists in blindness, but its dynamics and oculo-cerebral connectivity depend on visual status.

eNeuro·2026
Same author

Aligned representation of visual and tactile motion directions in hMT+/V5 and fronto-parietal regions.

Nature communications·2026
Same author

Onchocerca volvulus infection prevalence and intensity in Logo and Nyarambe Health Zones in Ituri, Democratic Republic of the Congo in 2010 and in 2021-2023: results of screening for clinical trials of moxidectin versus ivermectin.

Parasites & vectors·2026
Same author

Neural Architecture of Familiar Person Perception: Contributions of Unimodal and Multimodal Brain Regions.

Human brain mapping·2026
Same author

Integration of auditory and tactile inputs to localize haptic stimuli during active touch.

Attention, perception & psychophysics·2026
Same author

Connecting the dots: Similar visual orthographic acquisition for Braille or line junctions.

Psychonomic bulletin & review·2026
Same journal

Durable Response to Sotorasib in KRAS G12C-Mutant Intrahepatic Cholangiocarcinoma: A Case Report.

The oncologist·2026
Same journal

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

The oncologist·2026
Same journal

Prevalence, treatment and survival of Malignant Peripheral Nerve Sheath Tumor in the Danish neurofibromatosis type 1 population.

The oncologist·2026
Same journal

Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.

The oncologist·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
See all related articles

Related Experiment Video

Updated: Nov 19, 2025

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.5K

Implementing Historical Controls in Oncology Trials.

Olivier Collignon1,2, Anna Schritz1, Riccardo Spezia3

  • 1Luxembourg Institute of Health, Competence Center in Methodology and Statistics, Strassen, Luxembourg.

The Oncologist
|February 1, 2021
PubMed
Summary
This summary is machine-generated.

Single-arm oncology trials using historical controls can speed drug development and reduce patient enrollment. Careful study selection, statistical analysis, and regulatory engagement are crucial for success in high unmet need cases.

Keywords:
Bayesian designsDrug regulationHistorical controlsIndirect comparisonSingle-arm trials

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.0K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

17.8K

Related Experiment Videos

Last Updated: Nov 19, 2025

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.5K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.0K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

17.8K

Area of Science:

  • Oncology Drug Development
  • Clinical Trial Design

Background:

  • Oncology drug development is expanding beyond randomized trials to include single-arm trials for specific cancer subtypes.
  • These trials often utilize historical controls, presenting both opportunities and challenges.

Purpose of the Study:

  • To discuss the benefits and risks of using historical controls in single-arm oncology trials.
  • To outline regulatory and statistical considerations for this approach.

Main Methods:

  • Leveraging historical control data to potentially shorten development timelines and reduce patient enrollment.
  • Careful selection of past studies and prespecified statistical analyses accounting for heterogeneity.
  • Early engagement with regulatory bodies like the European Medicines Agency and U.S. Food and Drug Administration.

Main Results:

  • Historical controls can accelerate drug development and decrease patient numbers compared to randomized controlled trials.
  • This approach is most suitable for high unmet clinical need scenarios with well-characterized disease and objective endpoints.
  • Regulatory agencies have approved medicines based on non-randomized experiments, though evidentiary packages may be less comprehensive.

Conclusions:

  • Incorporating historical data in single-arm oncology trials offers potential benefits but requires meticulous planning.
  • Key elements for success include careful data selection, robust statistical methods addressing between-study variation, and proactive regulatory consultation.
  • This paradigm is best applied in situations of high unmet need or challenging experimental conditions where disease trajectory and endpoints are clearly defined.